McKesson Exits Europe with Norway Divestiture to NorgesGruppen
Event summary
- McKesson completed the sale of its Norwegian retail and distribution businesses to NorgesGruppen on January 30, 2026.
- The divestiture marks the final step in McKesson's exit from European operations, first announced on August 4, 2025.
- Proceeds will be allocated to expanding Oncology and Multispecialty and Biopharma Services growth platforms.
- Details of the transaction will be discussed during McKesson's Fiscal Third Quarter Earnings call on February 4, 2026.
The big picture
McKesson's complete exit from Europe underscores a broader trend of healthcare services companies streamlining operations to focus on higher-growth segments. The divestiture aligns with the company's strategy to concentrate on its core U.S. markets, particularly in oncology and biopharma services, where it sees greater potential for revenue growth and market share expansion. The transaction also reflects a broader industry shift towards consolidation and strategic realignment in response to evolving healthcare dynamics.
What we're watching
- Execution Risk
- How McKesson will integrate the divestiture proceeds into its Oncology and Multispecialty and Biopharma Services platforms.
- Market Focus
- Whether the exit from Europe will allow McKesson to better compete in its core U.S. markets.
- Financial Impact
- The pace at which the divestiture will affect McKesson's financial performance in the short to medium term.
Related topics